Frankfurt - Delayed Quote EUR

Aurinia Pharmaceuticals Inc. (IKAP.F)

7.06

+0.07

+(0.97%)

At close: April 25 at 9:39:01 PM GMT+2

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics are part of the Zacks Industry Outlook article.

Zacks 2 days ago

AUPH

HRTX

ESPR
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.

Zacks 3 days ago

PSTV

HRTX

AUPH
High Growth Tech Stocks To Watch In The US Market

Over the last 7 days, the United States market has experienced a drop of 9.4%, contributing to a 3.4% decline over the past year, although earnings are forecast to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies with strong fundamentals and innovative capabilities that can thrive despite current market challenges.

Simply Wall St. 19 days ago

OLO

AUPH

AVXL
Declining Stock and Decent Financials: Is The Market Wrong About Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)?

Aurinia Pharmaceuticals (NASDAQ:AUPH) has had a rough three months with its share price down 10%. But if you pay close...

Simply Wall St. 24 days ago

AUPH
Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March

We recently published a list of Insiders Are Spending Big: 15 Stocks Leading in March. In this article, we are going to take a look at where Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) stands against other stocks that are receiving the most insider investment in March. “The economy is strong overall and has made significant progress toward […]

Insider Monkey last month

AUPH
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?

Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks last month

XERS

AUPH
Signet Jewelers, Big Bear, and More Stocks See Action From Activist Investors

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

Barrons.com last month

SIG

AUPH

PBF
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting Point

Even though Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH ) recent earnings release was robust, the market didn't seem...

Simply Wall St. last month

AUPH
Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock?

Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

Zacks last month

AUPH
Results: Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

The annual results for Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) were released last week, making it a good time to...

Simply Wall St. last month

AUPH
Aurinia Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations

Aurinia Pharmaceuticals ( NASDAQ:AUPH ) Full Year 2024 Results Key Financial Results Revenue: US$235.1m (up 34% from FY...

Simply Wall St. last month

AUPH
Aurinia Pharmaceuticals Inc (AUPH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Aurinia Pharmaceuticals Inc (AUPH) reports a 33% revenue increase and a return to profitability, driven by robust LUPKYNIS sales and strategic financial management.

GuruFocus.com last month

AUPH
Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of 200% and 0.25%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

AUPH
Aurinia: Q4 Earnings Snapshot

The Edmonton, Alberta-based company said it had net income of 1 cent per share. Earnings, adjusted for restructuring costs, came to 9 cents per share. The results exceeded Wall Street expectations.

Associated Press Finance last month

AUPH
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

ROCKVILLE, Md. & EDMONTON, Alberta, February 27, 2025--Aurinia Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

Business Wire last month

AUPH
High Growth Tech Stocks In The United States Spotlighting Three Leaders

Over the last 7 days, the United States market has dropped 3.0%, yet it remains up by 18% over the past year with earnings forecasted to grow by 14% annually. In such a dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these promising growth trends.

Simply Wall St. last month

AUPH

CINT

MGTX
Is Aurinia Pharmaceuticals Inc. (AUPH) the Best Small-Cap Growth Stock to Buy Now?

We recently published a list of 10 Best Small-Cap Growth Stocks to Buy Now. In this article, we are going to take a look at where Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) stands against other best small-cap growth stocks to buy now. Are Small-Cap Stocks Poised for Growth? On November 4, 2024, Nick Sheridan, Portfolio Manager at […]

Insider Monkey last month

AUPH
Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

ROCKVILLE, Md. & EDMONTON, Alberta, February 20, 2025--Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Business Wire 2 months ago

AUPH
Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?

Corcept (CORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 2 months ago

CORT

AUPH
Aurinia (AUPH) Upgraded to Buy: Here's Why

Aurinia (AUPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 3 months ago

AUPH

Performance Overview

Return	IKAP.F	S&P 500 (^GSPC)
YTD	-18.03%	-6.06%
1-Year	+59.46%	+9.44%
3-Year	-28.22%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aurinia Pharmaceuticals Inc. (IKAP.F)

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

High Growth Tech Stocks To Watch In The US Market

Declining Stock and Decent Financials: Is The Market Wrong About Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)?

Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March

Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?

Signet Jewelers, Big Bear, and More Stocks See Action From Activist Investors

Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting Point

Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock?

Results: Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aurinia Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations

Aurinia Pharmaceuticals Inc (AUPH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates

Aurinia: Q4 Earnings Snapshot

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

High Growth Tech Stocks In The United States Spotlighting Three Leaders

Is Aurinia Pharmaceuticals Inc. (AUPH) the Best Small-Cap Growth Stock to Buy Now?

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?

Aurinia (AUPH) Upgraded to Buy: Here's Why

Performance Overview